Introduction

48
Onychomycosis (tinea unguium) is a chronic fungal infection of the nail characterized by 49 nail discoloration, thickening and deformity (1). The disease, although not life-50 threatening, can markedly affect quality of life and well-being (1). It is the most common 51 nail disorder in older adults, frequently involving several nails and affecting the toenail in 52 80% of cases (2). Onychomycosis can be caused by dermatophytes, nondermatophytes 53 and yeasts, and the species prevalence in nail infections varies with geographical location, 54 climate and migration (3). 55
Dermatophytes, mainly Trichophyton rubrum and Trichophyton mentagrophytes, are the 56 predominant causative agents of fingernail and toenail onychomycosis, accounting for 57 approximately 50-90% of cases, with infection prevalence in toenails much higher than in 58 fingernails (3-6). 59
The role of nondermatophytes and yeasts as sole causative agents of onychomycosis has 60 not been fully established and, in several cases, these organisms are considered to be 61 colonizing organisms or contaminants rather than pathogens (6, 7). However, in recent 62 years, yeasts have been increasingly recognized as pathogens in fingernail infections, as 63 well as other nondermatophytes (6, 8) . Isolation of an organisms from infected nail tissue 64
is not proof that it is the causative pathogen, and positive potassium hydroxide and 65 histopathological examination demonstrating fungus invasion of the nail plate are usually 66 on December 20, 2017 by guest http://aac.asm.org/
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Fungal isolates post-efinaconazole therapy. Thirteen T. rubrum clinical isolates from 133 toenail onychomycosis patients treated topically with efinaconazole were tested for 134 efinaconazole susceptibility in vitro. These isolates were obtained from two identical, 135 multi center, multi country, vehicle-controlled Phase 3 clinical trials with topical 136 efinaconazole 10% applied daily to toenails for 48 weeks. Isolates were recovered at the 137 end of treatment (study week 48) and four weeks afterwards (study week 52). 138
139
In vitro antifungal susceptibility. Testing was conducted using the broth dilution 140 minimum inhibitory concentration (MIC) assay following the standard procedures as 141 described in the Clinical and Laboratory Standards Institute (CLSI) documents M38-A2 142 and M27-A3. Clinical isolates were tested against efinaconazole, amorolfine, ciclopirox, 143 itraconazole and terbinafine. Drug stock solutions (100x or 200x) in DMSO were serially 144 diluted 1/2 in DMSO to obtain a range of ten concentrations, which were further diluted 145 1/100 or 1/50 in RPMI media. The final DMSO concentration was 0.5% or 1% in the 146 drug microdilution plates. Concurrent DMSO vehicle control wells were included as the 147 100% growth controls. The MIC was determined in fungal cultures at 96 hours post-148 inoculation for dermatophytes. For nondermatophytes, the MIC was determined at 48 149 hours except for A. potronii and S. brumptii (7 days). For yeasts, the MIC was determined 150 at 24 and 48 hours except for C. neoformance (72 hours isolates from onychomycosis patients treated with efinaconazole were determined. A 185 total of 13 T. rubrum isolates were tested, which were recovered from patient toenails 186 following once daily topical application of efinaconazole for 48 weeks (immediately after 187 treatment cessation and four weeks afterwards). The efinaconazole MICs ranged from 188 ≤0.002 to 0.015 µg/ml and were within the range for isolates from untreated patients. 189
Ten of these 13 isolates had a corresponding isolate collected prior to treatment from the 190 same patient toenail; the MIC of 6 increased minimally at post-treatment relative to 191 screening (highest change was from ≤0.002 to 0.008 µg/ml), 1 decreased and 3 did not 1000-fold lower than the comparator drugs, while the MIC 90 was 2-to 66-fold lower. At 232 48 hours, efinaconazole was also more potent than the comparator drugs; MIC 50 of 233 efinaconazole was 4-to 1000-fold lower. However, a comparison could not be made 234 based on MIC 90 because it was higher than the top concentration tested for three drugs 235 (Table 2) . 236
The efinaconazole MIC values were significantly lower when compared to those of the 237 comparator drugs both at 24 and 48 hours (p<0.001). As expected, terbinafine had the 238 lowest activity in vitro among all test agents evaluated, (i.e., highest MICs) against C. 239 albicans. Among the comparator drugs, terbinafine exhibited the greatest difference with 240 efinaconazole, with MIC 50 and MIC 90 that were 1000-and 66-fold higher, respectively. 241
We further compared the susceptibility patterns of efinaconazole and itraconazole at 48 242 hours. The breakpoint for itraconazole resistance in C. albicans is >0.5 µg/ml, and a total 243 of 15 isolates tested (14%) were considered resistant. In this case, the susceptibility to 244 these two drugs were well correlated (r = 0.85) ( Table 3) . active against all of the isolates tested with most MICs of 1 µg/ml or lower (Table 4) We further characterized efinaconazole's antifungal spectrum of activity in other 33 304 fungal species. Overall, efinaconazole was active against all species tested with MIC 305 ranges of ≤0.002 to 0.5 µg/ml for other dermatophytes, ≤0.002 to 0.13 µg/ml for other 306 yeasts and 0.0078 to 2 µg/ml for nondermatophyte molds. Efinaconazole was generally 307 more active against these molds than amorolfine, ciclopirox, itraconazole and terbinafine, 308 and its antifungal spectrum was broader than that of the existing drugs. 309
Although efinaconazole and terbinafine had comparable antifungal activity against 310 dermatophytes and nondermatophytes, their activity was markedly different against 311 on December 20, 2017 by guest http://aac.asm.org/ Downloaded from Candida spp. Efinaconazole was significantly more potent than terbinafine, with MICs 312 mostly <0.1 µg/ml and ≥1 µg/ml, respectively. Terbinafine was previously found to be 313 inactive against C. glabrata, C. krusei and C. tropicalis when tested at concentrations as 314 high as 128 µg/ml. In contrast, efinaconazole has potent antifungal activity against these 315 species, as well as other yeast in which terbinafine is also active. 316
In vitro studies have reported that some fungal clinical isolates, including Candida 317 species, with reduced susceptibility to one azole antifungal agent may also be less 318 susceptible to other azoles (13). The MICs of efinaconazole against C. albicans 319 correlated well with those of itraconazole, another azole, although efinaconazole showed 320 a one order of magnitude higher potency. There are no breakpoints established for 321 efinaconazole. However, there were 15 resistant C. albicans isolates tested based on a 322 resistant breakpoint of >0.5 µg/ml, 12 of which were also the least susceptible (MIC ≥ 323 0.25 µg/ml) to efinaconazole (Table 3) 
